Stoke Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Stoke Therapeutics, Inc. (STOK) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 37.45 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-10
- Stoke Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 37.45M shares, a 2.20% increase year-over-year.
- Stoke Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 36.84M shares, a 4.98% increase year-over-year.
- Stoke Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 36.76M shares, a 10.48% increase year-over-year.
- Stoke Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 36.71M shares, a 11.05% increase year-over-year.
- Stoke Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 36.74M shares, a 9.71% increase from fiscal 2020.
- Stoke Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 33.49M shares, a 86.34% increase from fiscal 2019.
- Stoke Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 17.97M shares, a 2433.56% increase from fiscal 2018.
- Stoke Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 709.34K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 37.45M shares 10-Q · filed 2022-05-10 | 37.14M shares derived: average of 2 quarters · filed 2022-05-10 | 37.01M shares derived: average of 3 quarters · filed 2022-05-10 | 36.94M shares derived: average of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 36.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 36.80M shares derived: average of 2 quarters · filed 2022-03-10 | 36.77M shares derived: average of 3 quarters · filed 2022-03-10 | 36.74M shares 10-K · filed 2022-03-10 |
| 2021-09-30 | 36.76M shares 10-Q · filed 2021-11-08 | 36.73M shares derived: average of 2 quarters · filed 2021-11-08 | 36.71M shares 10-Q · filed 2021-11-08 | 36.30M shares derived: average of 4 quarters · filed 2022-05-10 |
| 2021-06-30 | 36.71M shares 10-Q · filed 2021-08-10 | 36.68M shares 10-Q · filed 2021-08-10 | 36.15M shares derived: average of 3 quarters · filed 2022-05-10 | 35.43M shares derived: average of 4 quarters · filed 2022-05-10 |
| 2021-03-31 | 36.64M shares 10-Q · filed 2022-05-10 | 35.87M shares derived: average of 2 quarters · filed 2022-05-10 | 35.00M shares derived: average of 3 quarters · filed 2022-05-10 | 34.52M shares derived: average of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | 35.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 34.18M shares derived: average of 2 quarters · filed 2022-03-10 | 33.81M shares derived: average of 3 quarters · filed 2022-03-10 | 33.49M shares 10-K · filed 2022-03-10 |
| 2020-09-30 | 33.27M shares 10-Q · filed 2021-11-08 | 33.16M shares derived: average of 2 quarters · filed 2021-11-08 | 32.95M shares 10-Q · filed 2021-11-08 | 33.03M shares derived: average of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | 33.05M shares 10-Q · filed 2021-08-10 | 32.98M shares 10-Q · filed 2021-08-10 | 32.95M shares derived: average of 3 quarters · filed 2021-08-10 | 32.89M shares derived: average of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | 32.90M shares 10-Q · filed 2021-05-10 | 32.90M shares derived: average of 2 quarters · filed 2021-05-10 | 32.84M shares derived: average of 3 quarters · filed 2021-05-10 | 25.90M shares derived: average of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | 32.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | 32.81M shares derived: average of 2 quarters · filed 2021-03-09 | 23.57M shares derived: average of 3 quarters · filed 2021-03-09 | 17.97M shares 10-K · filed 2021-03-09 |
| 2019-09-30 | 32.71M shares 10-Q · filed 2020-11-12 | 18.90M shares derived: average of 2 quarters · filed 2020-11-12 | 12.99M shares 10-Q · filed 2020-11-12 | 9.85M shares derived: average of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | 5.08M shares 10-Q · filed 2020-08-10 | 2.97M shares 10-Q · filed 2020-08-10 | 2.23M shares derived: average of 3 quarters · filed 2020-08-10 | 1.84M shares derived: average of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | 833.47K shares 10-Q · filed 2020-05-15 | 796.64K shares derived: average of 2 quarters · filed 2020-05-15 | 764.09K shares derived: average of 3 quarters · filed 2020-05-15 | 745.87K shares derived: average of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | 759.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | 729.39K shares derived: average of 2 quarters · filed 2020-03-23 | 716.67K shares derived: average of 3 quarters · filed 2020-03-23 | 709.34K shares 10-K · filed 2020-03-23 |
| 2018-09-30 | 698.97K shares 10-Q · filed 2019-11-12 | 695.09K shares derived: average of 2 quarters · filed 2019-11-12 | 692.51K shares 10-Q · filed 2019-11-12 | |
| 2018-06-30 | 691.21K shares 10-Q · filed 2019-08-14 | 689.11K shares 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |